Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · Real-Time Price · USD
3.910
+0.340 (9.52%)
At close: Nov 13, 2026, 4:00 PM EST
3.920
+0.010 (0.26%)
After-hours: Nov 13, 2026, 7:59 PM EST
Aquestive Therapeutics Stock Forecast
Stock Price Forecast
According to 9 analysts polled by S&P Global, Aquestive Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $9.33. The average 1-year stock price forecast is 138.70% higher than the current stock price, while the lowest is $6.00 (+53.45%) and the highest is $11 (+181.33%).
Price Target: $9.33 (+138.70%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Aquestive Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $10 | Buy | Reiterates | $10 | +155.75% | Nov 9, 2026 |
| Leerink Partners | Leerink Partners | Buy Reiterates $11 | Buy | Reiterates | $11 | +181.33% | Nov 5, 2026 |
Unknown Analyst Oppenheimer No rating | Oppenheimer | Buy Maintains $9 | Buy | Maintains | $9 | +130.18% | Nov 5, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Reiterates $10 | Buy | Reiterates | $10 | +155.75% | Sep 17, 2026 |
| Lake Street | Lake Street | Buy Maintains $6 | Buy | Maintains | $6 | +53.45% | Sep 17, 2026 |
Financial Forecast
Revenue This Year
49.50M
from 44.55M
Increased by 11.13%
Revenue Next Year
69.64M
from 49.50M
Increased by 40.69%
EPS This Year
-0.36
from -0.59
EPS Next Year
-0.57
from -0.36
EPS and Forward PE are based on non-GAAP adjusted numbers.